Capecitabine and oxaliplatin (XEOLX) in adjuvant gastric cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Bounedjar
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors A. Bounedjar
  • CHU Blida, Blida, Algeria, /

Abstract

Adjuvant chemotherapy with XELOX (capecitabine plus oxaliplatin) has been shown to be beneficial following resection of gastric cancer in this study we evaluated the feasibility and tolerance of XELOX in adjuvant to patients with resected gastric cancer in four medical oncology department.